Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again
05:10pm, Tuesday, 24'th Jan 2023 Zacks Investment Research
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Where Biogen Stands With Analysts
05:00pm, Tuesday, 24'th Jan 2023 Benzinga
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
4
0
0
Last 30D
0
1
0
Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again
01:33pm, Tuesday, 24'th Jan 2023
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2 Stocks to Buy with Recent Fair Value Increases
08:00am, Tuesday, 24'th Jan 2023
Morningstar analysts just raised their intrinsic values on these names. 00:00 Introduction 01:02 Host Hotels & Resorts (HST) 01:38 Biogen Stock (BIIB) Susan Dziubinski: Morningstar analysts calculate
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
11:20am, Monday, 23'rd Jan 2023 Zacks Investment Research
Smart Beta ETF report for XBI
Eating these simple foods may slow Alzheimer's by a third
05:07pm, Saturday, 21'st Jan 2023 MarketWatch
New research shows that people who ate certain foods were less likely to get dementia.
Why the FDA didn't grant an approval to Lilly's Alzheimer's drug
02:19pm, Saturday, 21'st Jan 2023 MarketWatch
The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year
FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug
05:52pm, Friday, 20'th Jan 2023 Zacks Investment Research
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Tech Stocks Get Netflix Boost Amid Jittery Wider Market On Friday, Dow Stares At 4th Straight Loss
11:30am, Friday, 20'th Jan 2023 Benzinga
U.S. stocks look set for a positive start on Friday, reversing course from the sell-off seen in the past three sessions.
What Happened: Traders may have to contend with Fed speeches and housing mark
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
11:15pm, Thursday, 19'th Jan 2023 Zacks Investment Research
Biogen Inc. (BIIB) closed the most recent trading day at $280.13, moving -1.18% from the previous trading session.
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
02:20pm, Thursday, 19'th Jan 2023 The Motley Fool
The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.
If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today
10:25am, Thursday, 19'th Jan 2023 The Motley Fool
The stock hasn't been a great investment in recent years, but there's hope for a brighter future.
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
09:20am, Thursday, 19'th Jan 2023
The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
10:55am, Tuesday, 17'th Jan 2023 The Motley Fool
The fountain of youth might not be a myth in the future.
Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan
05:33pm, Monday, 16'th Jan 2023 Zacks Investment Research
Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.
